ClinicalTrials.gg
RecruitingNCT05904353Updated Feb 5, 2024

A Study to Improve the Collaboration Between Primary and Secondary Health Care on the Treatment of Osteoporosis After a Hip Fracture.

An interventional study of Ambulant nurse-assisted administration of zoledronic acid and Usual care in Hip Fractures, Osteoporosis and Zoledronic Acid, sponsored by University Hospital, Akershus. Recruiting at 1 site in Norway. Open to participants aged 75 Years and older. Per ClinicalTrials.gov, last updated 2024-02-05.

Sponsored by University Hospital, Akershus · Not applicable, Interventional, and Health services research

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 11 months ago, but the record still lists the study as recruiting.
  • Started Jan 2024; still recruiting 2 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
75 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 30 studies in Hip Fractures with a site in Norway — 4 open to participants now, 6 under way, none of them phase 3. Hip Fractures · Norway.

Planned enrollment
13th of 25
200 · median 200
Started
2024
with 1 other
No phase
20 of 30
4 open now
Registered
28th of 30
by date
Lead sponsor
2 of 30
University Hospital, Akershus

Among the 30 studies in Hip Fractures with a site in Norway, this one is the 13th largest by planned enrollment of the 25 interventional ones that give a count, is one of 2 that started in 2024, is one of 20 with no phase, and was the 28th registered.

Hip Fractures

843 studies on the registry are indexed under Hip Fractures; 166 are open to participants now.

Browse Hip Fractures studies →

Open to participants now

4 of the 30 studies in Hip Fractures with a site in Norway are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Norway have not opened yet or have stopped. Only those recruiting at a site in Norway →

Who these studies take

Of the 104 Hip Fractures studies recruiting now, 82 (79%) set no upper age limit and 6 (6%) stop at 75 or younger; 12 take children under 18; 9 take healthy volunteers.

This study: 75 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Hip Fractures with a site in Norway, or all of them as a file.
02

Study summary

This is a study to improve the collaboration between primary and secondary health care on the treatment of osteoporosis after a hip fracture. In Akershus University Hospital, patients 75 years or older with a hip fracture, are offered treatment with an infusion of zoledronic acid 5mg, combined with vitamin D and calcium supplements, to prevent new fractures. General practitioners (GPs) are requested to take care of the follow-up on this treatment with annual infusions of zoledronic acid for 3 years.

In the opinion of the investigators, it is expedient, safe, and sensible for parts of the subsequent treatment to be provided by GPs. If hospitals take responsibility for initiating the treatment, the investigators believe that most of the subsequent monitoring and continuance of treatment can be conducted by the primary healthcare service. Despite this, the investigators suspect that many patients do not get their annual infusions of zoledronic acid after discharge from the hospital.

This quality assurance study aims to test a new system where ambulant nurses from the hospital support the GP in treating osteoporosis with the administration of zoledronic acid in the following 3 years after femoral neck fractures. Through the project, the investigators will create procedures for the administration and follow-up of zoledronic acid fitted in the setting of the GP office.

The design is a cluster randomized controlled study (RCT) where the regions are prospectively randomized to either intervention or control regions. Patients ≥ 75 years, which suffer a femoral neck fracture, are identified in our Department of Orthopedic Surgery, where they are provided the first infusion of zoledronic acid 5 mg and proposed participation in the study. Patients from the intervention regions will be followed by the protocol of ambulant nurse-assisted administration of zoledronic acid. Patients from the control regions are offered the usual care. Both patients from the control and intervention regions are asked to fill out a questionnaire after 1 year. The questionnaire will ask if the patient has got zoledronic acid as encouraged in the medical journal after discharge from the hospital. The primary study outcome is if the patients are offered treatment at a one-year follow-up or not.

Sample size calculation estimates a total sample of 130 patients based on a minimal clinically important difference of 20% follow-up between the groups. Because of high mortality, the investigators estimate the need for 200 patients.

The investigators hypothesize that the one-year follow-up is better in the intervention group than in the control group.

03

Conditions studied

  • Hip Fractures
  • Osteoporosis
  • Zoledronic Acid
  • Ambulant Nurse
  • Case Manager
04

Who can participate

Ages eligible
75 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients 75 years or older with a hip fracture

Exclusion criteria

Exclusion Criteria:

  • Refuse treatment
  • Another treatment of osteoporosis is indicated
  • Guest patient, do not live in the admission area
  • Dementia
05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Care provider, Investigator)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    Cluster randomized intervention regions

    Patients from the intervention regions will be followed the protocol of ambulant nurse-assisted administration of zoledronic acid

    Procedure: Ambulant nurse-assisted administration of zoledronic acid

  • Active comparator
    Cluster randomized control regions

    Patients from the control regions are followed as usual. General practitioners are requested to take care of the follow-up, through the patients and the discharge summary, with annual infusions of zoledronic acid.

    Procedure: Usual care

Interventions

  • ProcedureAmbulant nurse-assisted administration of zoledronic acid

    Patients from the intervention regions will be followed by the protocol of ambulant nurse-assisted administration of zoledronic acid.

  • ProcedureUsual care

    General practitioners are requested to take care of the follow-up, through the patients and the discharge summary, with annual infusions of zoledronic acid.

06

What researchers measure

Primary outcomes

  1. Number of participants offered treatment after one year

    The primary study outcome is the number of participants offered treatment with zoledronic acid after one-year.

    Time frame: One year

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2024 (actual). Primary completion is estimated for Dec 2025, 23 months after the start.

Of 221 non-industry interventional studies with no phase under Hip Fractures, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 55. This study's planned 23 months is below that.

Counting every sponsor, half of 237 studies reached it within 29 months; a quarter within 10 and three quarters within 57.

How these figures are worked out, and which studies are left out of them.

Registered
May 5, 2023
First posted
Jun 15, 2023
StartActual
Jan 1, 2024
Primary completionEst.
Dec 2025
CompletionEst.
Dec 2026
Last update
Feb 5, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 5, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05904353
Responsible party
Jakob Vangen Nordbø (Principal Investigator, University Hospital, Akershus) — Principal investigator
First posted
Jun 15, 2023
Start date
Jan 1, 2024
Primary completion
Dec 2025 (estimated)
Completion
Dec 2026 (estimated)
Last update
Feb 5, 2024

Study contacts

Jakob Vangen Nordbø, MD
Contact
Jakob.Vangen.Nordbo@ahus.no
+4797124493
Lene Gjelseth Dalbak, MD, PHD
study chair · University Hospital, Akershus
Jakob Vangen Nordbø, MD
principal investigator · University Hospital, Akershus

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion